Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-06-11

KalVista Pharmaceuticals, Inc. (KALV)

CEO Benjamin Palleiko was paid $5,094,999 in fiscal year 2025, ↓ down 24.8% from fiscal year 2024 (SEC filing 0001193125-26-197556 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$5,094,999 ↓
Benjamin Palleiko total, FY2025
—
CEO pay percentile vs peers
—
CEO-to-median pay ratio
89.4%
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Benjamin Palleiko (Chief Executive Officer), FY2025 total compensation $5,094,999 (base salary $477,202) [exec_comp, SEC accession 0001193125-26-197556, filed 2026-04-30]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

KALV's next annual pay disclosure, estimated April 30, 2027.est. Filing ↗

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Benjamin Palleiko$688,272$660,741$3,731,160$0$0$0$14,826$5,094,999
Chief Executive Officer
Paul Audhya523,016313,8101,938,20000014,0682,789,094
Chief Medical Officer
Brian Piekos296,346184,000802,400851,420009,9672,144,133
Chief Financial Officer
Bilal Arif124,33352,0000778,450000954,783
Chief Operating Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY2024→2025
Benjamin Palleiko$5,094,999$6,772,197$2,420,747↓ −1,677,198
Paul Audhya2,789,0941,833,9741,833,974↑ +955,120
Brian Piekos2,144,133———
Bilal Arif954,783———

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read KalVista Pharmaceuticals, Inc.'s Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper KALV reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

Get the KalVista Pharmaceuticals, Inc. Peer Teardown Report

$5,094,999 Benjamin Palleiko total, FY2025

$199

The free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.

Data as of June 11, 2026 · Source: 0001193125-26-197556 · Velarion Executive Compensation Database, deposited on Zenodo (doi:10.5281/zenodo.22283855).

Reports for KALV

Every report below is generated from the same filings as the free brief above, at the moment of purchase. What each one adds:

Executive Compensation ReportThe free page is the headline figures. The report is every award, peer and vote combined into one document you can hand to a committee.$1,500 →Reverse Peer AnalysisThe free page is the one line. The analysis reads every company that names this one in its own peer group.$299 →Peer Teardown ReportThe free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.$199 →
KALVon Velarion Intel, free → The platform reading of this company, beside the same data as a subscription.

Order KALV

Pick the report, add the email the receipt and the PDF go to, and pay by card on Stripe.

Receipt, invoice, and report delivery. Guest checkout, no account required, secure payment by Stripe.

How we handle your data → Privacy

Companies that benchmark against KALV
9 companies name KALV as a compensation peer

The list of companies that name KALV as a peer is temporarily unavailable — recheck shortly.

Get the KalVista Pharmaceuticals, Inc. Executive Compensation Report

$1,500

Buy the report - $1,500Both reports - $2,400
01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2025 total
Brian J. G. PereiraIndependent Director—
Edward W. UnkartIndependent Director—
Laurence ReidIndependent Director—
Nancy StuartIndependent Director—
Patrick TreanorIndependent Director—
William FaireyIndependent Director—
02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Benjamin PalleikoDirector2026-05-11D7,120$0$0Derivative, Class A CommonForm 4 ↗
Benjamin PalleikoDirector2026-05-11A7,120——CommonForm 4 ↗
Benjamin PalleikoDirector2026-05-12D3,3222788,731CommonForm 4 ↗
Benjamin PalleikoDirector2026-05-17D2,41900Derivative, Class A CommonForm 4 ↗
Benjamin PalleikoDirector2026-05-17A2,419——CommonForm 4 ↗
Paul AudhyaChief Medical Officer2026-05-17A2,419——CommonForm 4 ↗
Dividend-equivalent accruals2026-05-17—1,774——1 insider, 1 accrual row
Christopher YeaChief Development Officer2026-05-17A1,774——CommonForm 4 ↗
Paul AudhyaChief Medical Officer2026-05-17D2,41900Derivative, Class A CommonForm 4 ↗
Christopher YeaChief Development Officer2026-05-18D1,1082729,650CommonForm 4 ↗
Benjamin PalleikoDirector2026-05-18D1,1292730,212CommonForm 4 ↗
Paul AudhyaChief Medical Officer2026-05-18D1,0322727,616CommonForm 4 ↗
Brian PiekosChief Financial Officer2026-05-21D5,00000Derivative, Class A CommonForm 4 ↗
Paul AudhyaChief Medical Officer2026-05-21D6,25000Derivative, Class A CommonForm 4 ↗
Christopher YeaChief Development Officer2026-05-21A3,750——CommonForm 4 ↗
Nicole SweenyChief Commercial Officer2026-05-21D6,25000Derivative, Class A CommonForm 4 ↗
Nicole SweenyChief Commercial Officer2026-05-21A6,250——CommonForm 4 ↗
Paul AudhyaChief Medical Officer2026-05-21A6,250——CommonForm 4 ↗
Benjamin PalleikoDirector2026-05-21D23,25000Derivative, Class A CommonForm 4 ↗
Benjamin PalleikoDirector2026-05-21A23,250——CommonForm 4 ↗
Brian PiekosChief Financial Officer2026-05-21A5,000——CommonForm 4 ↗
Christopher YeaChief Development Officer2026-05-21D3,75000Derivative, Class A CommonForm 4 ↗
Brian PiekosChief Financial Officer2026-05-22D1,4892739,882CommonForm 4 ↗
Nicole SweenyChief Commercial Officer2026-05-22D1,8612749,846CommonForm 4 ↗
Paul AudhyaChief Medical Officer2026-05-22D5,00000Derivative, Class A CommonForm 4 ↗
Nicole SweenyChief Commercial Officer2026-05-22D5,00000Derivative, Class A CommonForm 4 ↗
Nicole SweenyChief Commercial Officer2026-05-22A5,000——CommonForm 4 ↗
Christopher YeaChief Development Officer2026-05-22D3,12500Derivative, Class A CommonForm 4 ↗
Christopher YeaChief Development Officer2026-05-22D2,3582763,158CommonForm 4 ↗
Benjamin PalleikoDirector2026-05-22D10,92627292,646CommonForm 4 ↗
Christopher YeaChief Development Officer2026-05-22A3,125——CommonForm 4 ↗
Paul AudhyaChief Medical Officer2026-05-22D2,6852771,916CommonForm 4 ↗
Paul AudhyaChief Medical Officer2026-05-22A5,000——CommonForm 4 ↗
Paul AudhyaChief Medical Officer2026-05-26D2,2392759,955CommonForm 4 ↗
Christopher YeaChief Development Officer2026-05-26D1,9662752,645CommonForm 4 ↗
Nicole SweenyChief Commercial Officer2026-05-26D1,4892739,872CommonForm 4 ↗
Christopher YeaChief Development Officer2026-05-27D33,80000Derivative, Class A CommonForm 4 ↗
Christopher YeaChief Development Officer2026-05-27D33,80027905,225CommonForm 4 ↗
Christopher YeaChief Development Officer2026-05-27A33,8007238,966CommonForm 4 ↗
Edward W. UnkartDirector2026-06-11D30,000——Derivative, Class A CommonForm 4 ↗
Edward W. UnkartDirector2026-06-11D7,000——Derivative, Class A CommonForm 4 ↗
Bilal ArifChief Operations Officer2026-06-11D100,000——Derivative, Class A CommonForm 4 ↗
Nicole SweenyChief Commercial Officer2026-06-11D93,750——Derivative, Class A CommonForm 4 ↗
Patrick TreanorDirector2026-06-11D17,000——Derivative, Class A CommonForm 4 ↗
Bethany SensenigDirector2026-06-11D45,000——Derivative, Class A CommonForm 4 ↗
Paul AudhyaChief Medical Officer2026-06-11D68,750——Derivative, Class A CommonForm 4 ↗
Paul AudhyaChief Medical Officer2026-06-11D40,000——Derivative, Class A CommonForm 4 ↗
Paul AudhyaChief Medical Officer2026-06-11D150,26000CommonForm 4 ↗
Brian JG PereiraDirector2026-06-11D30,000——Derivative, Class A CommonForm 4 ↗
Brian JG PereiraDirector2026-06-11D10,000——Derivative, Class A CommonForm 4 ↗
Brian JG PereiraDirector2026-06-11D10,000——Derivative, Class A CommonForm 4 ↗
Nancy StuartDirector2026-06-11D10,000——Derivative, Class A CommonForm 4 ↗
Nancy StuartDirector2026-06-11D10,000——Derivative, Class A CommonForm 4 ↗
Edward W. UnkartDirector2026-06-11D10,000——Derivative, Class A CommonForm 4 ↗
Brian PiekosChief Financial Officer2026-06-11D93,750——Derivative, Class A CommonForm 4 ↗
Brian PiekosChief Financial Officer2026-06-11D55,000——Derivative, Class A CommonForm 4 ↗
Christopher YeaChief Development Officer2026-06-11D41,250——Derivative, Class A CommonForm 4 ↗
Christopher YeaChief Development Officer2026-06-11D18,920——Derivative, Class A CommonForm 4 ↗
Christopher YeaChief Development Officer2026-06-11D20,000——Derivative, Class A CommonForm 4 ↗
Christopher YeaChief Development Officer2026-06-11D27,900——Derivative, Class A CommonForm 4 ↗
Christopher YeaChief Development Officer2026-06-11D52,600——Derivative, Class A CommonForm 4 ↗
Christopher YeaChief Development Officer2026-06-11D229,91800CommonForm 4 ↗
Benjamin PalleikoDirector2026-06-11D304,688——Derivative, Class A CommonForm 4 ↗
Benjamin PalleikoDirector2026-06-11D92,560——Derivative, Class A CommonForm 4 ↗
Benjamin PalleikoDirector2026-06-11D125,001——Derivative, Class A CommonForm 4 ↗
Benjamin PalleikoDirector2026-06-11D113,920——Derivative, Class A CommonForm 4 ↗
Benjamin PalleikoDirector2026-06-11D40,000——Derivative, Class A CommonForm 4 ↗
Benjamin PalleikoDirector2026-06-11D25,800——Derivative, Class A CommonForm 4 ↗
Benjamin PalleikoDirector2026-06-11D37,500——Derivative, Class A CommonForm 4 ↗
Benjamin PalleikoDirector2026-06-11D85,000——Derivative, Class A CommonForm 4 ↗
Benjamin PalleikoDirector2026-06-11D75,000——Derivative, Class A CommonForm 4 ↗
Benjamin PalleikoDirector2026-06-11D33,750——Derivative, Class A CommonForm 4 ↗
Benjamin PalleikoDirector2026-06-11D71,700——Derivative, Class A CommonForm 4 ↗
Benjamin PalleikoDirector2026-06-11D33,800——Derivative, Class A CommonForm 4 ↗
Benjamin PalleikoDirector2026-06-11D47,354——Derivative, Class A CommonForm 4 ↗
Brian PiekosChief Financial Officer2026-06-11D100,000——Derivative, Class A CommonForm 4 ↗
Christopher YeaChief Development Officer2026-06-11D80,000——Derivative, Class A CommonForm 4 ↗
Christopher YeaChief Development Officer2026-06-11D31,000——Derivative, Class A CommonForm 4 ↗
Benjamin PalleikoDirector2026-06-11D479,98900CommonForm 4 ↗
Edward W. UnkartDirector2026-06-11D10,000——Derivative, Class A CommonForm 4 ↗
Nicole SweenyChief Commercial Officer2026-06-11D59,29100CommonForm 4 ↗
Paul AudhyaChief Medical Officer2026-06-11D25,800——Derivative, Class A CommonForm 4 ↗
Brian JG PereiraDirector2026-06-11D10,000——Derivative, Class A CommonForm 4 ↗
Brian JG PereiraDirector2026-06-11D7,000——Derivative, Class A CommonForm 4 ↗
Patrick TreanorDirector2026-06-11D30,000——Derivative, Class A CommonForm 4 ↗
Patrick TreanorDirector2026-06-11D10,000——Derivative, Class A CommonForm 4 ↗
Brian PiekosChief Financial Officer2026-06-11D21,66100CommonForm 4 ↗
Christopher YeaChief Development Officer2026-06-11D25,000——Derivative, Class A CommonForm 4 ↗
Benjamin PalleikoDirector2026-06-11D20,000——Derivative, Class A CommonForm 4 ↗
Christopher YeaChief Development Officer2026-06-11D60,000——Derivative, Class A CommonForm 4 ↗
Christopher YeaChief Development Officer2026-06-11D53,500——Derivative, Class A CommonForm 4 ↗
Paul AudhyaChief Medical Officer2026-06-11D93,750——Derivative, Class A CommonForm 4 ↗
Paul AudhyaChief Medical Officer2026-06-11D100,000——Derivative, Class A CommonForm 4 ↗
Benjamin PalleikoDirector2026-06-11D255,750——Derivative, Class A CommonForm 4 ↗
Benjamin PalleikoDirector2026-06-11D29,611——Derivative, Class A CommonForm 4 ↗
Nancy StuartDirector2026-06-11D14,000——Derivative, Class A CommonForm 4 ↗
Benjamin PalleikoDirector2026-06-11D52,600——Derivative, Class A CommonForm 4 ↗
Edward W. UnkartDirector2026-06-11D10,000——Derivative, Class A CommonForm 4 ↗
Edward W. UnkartDirector2026-06-11D7,000——Derivative, Class A CommonForm 4 ↗
Edward W. UnkartDirector2026-06-11D7,000——Derivative, Class A CommonForm 4 ↗
Edward W. UnkartDirector2026-06-11D10,000——Derivative, Class A CommonForm 4 ↗
Edward W. UnkartDirector2026-06-11D6,000——Derivative, Class A CommonForm 4 ↗
Edward W. UnkartDirector2026-06-11D12,000——Derivative, Class A CommonForm 4 ↗
Laurence ReidDirector2026-06-11D17,000——Derivative, Class A CommonForm 4 ↗
Bilal ArifChief Operations Officer2026-06-11D49,000——Derivative, Class A CommonForm 4 ↗
Nicole SweenyChief Commercial Officer2026-06-11D68,750——Derivative, Class A CommonForm 4 ↗
Nicole SweenyChief Commercial Officer2026-06-11D40,000——Derivative, Class A CommonForm 4 ↗
Nicole SweenyChief Commercial Officer2026-06-11D100,000——Derivative, Class A CommonForm 4 ↗
Patrick TreanorDirector2026-06-11D10,000——Derivative, Class A CommonForm 4 ↗
William FaireyDirector2026-06-11D30,000——Derivative, Class A CommonForm 4 ↗
William FaireyDirector2026-06-11D10,000——Derivative, Class A CommonForm 4 ↗
William FaireyDirector2026-06-11D17,000——Derivative, Class A CommonForm 4 ↗
Brian JG PereiraDirector2026-06-11D10,000——Derivative, Class A CommonForm 4 ↗
Brian JG PereiraDirector2026-06-11D14,000——Derivative, Class A CommonForm 4 ↗
Nancy StuartDirector2026-06-11D30,000——Derivative, Class A CommonForm 4 ↗
Nancy StuartDirector2026-06-11D10,000——Derivative, Class A CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

View all 116 transactions
InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Benjamin PalleikoDirector2026-05-11D7,120$0$0Derivative, Class A CommonForm 4 ↗
Benjamin PalleikoDirector2026-05-11A7,120——CommonForm 4 ↗
Benjamin PalleikoDirector2026-05-12D3,3222788,731CommonForm 4 ↗
Benjamin PalleikoDirector2026-05-17D2,41900Derivative, Class A CommonForm 4 ↗
Benjamin PalleikoDirector2026-05-17A2,419——CommonForm 4 ↗
Paul AudhyaChief Medical Officer2026-05-17A2,419——CommonForm 4 ↗
Christopher YeaChief Development Officer2026-05-17D1,77400Derivative, Class A CommonForm 4 ↗
Christopher YeaChief Development Officer2026-05-17A1,774——CommonForm 4 ↗
Paul AudhyaChief Medical Officer2026-05-17D2,41900Derivative, Class A CommonForm 4 ↗
Christopher YeaChief Development Officer2026-05-18D1,1082729,650CommonForm 4 ↗
Benjamin PalleikoDirector2026-05-18D1,1292730,212CommonForm 4 ↗
Paul AudhyaChief Medical Officer2026-05-18D1,0322727,616CommonForm 4 ↗
Brian PiekosChief Financial Officer2026-05-21D5,00000Derivative, Class A CommonForm 4 ↗
Paul AudhyaChief Medical Officer2026-05-21D6,25000Derivative, Class A CommonForm 4 ↗
Christopher YeaChief Development Officer2026-05-21A3,750——CommonForm 4 ↗
Nicole SweenyChief Commercial Officer2026-05-21D6,25000Derivative, Class A CommonForm 4 ↗
Nicole SweenyChief Commercial Officer2026-05-21A6,250——CommonForm 4 ↗
Paul AudhyaChief Medical Officer2026-05-21A6,250——CommonForm 4 ↗
Benjamin PalleikoDirector2026-05-21D23,25000Derivative, Class A CommonForm 4 ↗
Benjamin PalleikoDirector2026-05-21A23,250——CommonForm 4 ↗
Brian PiekosChief Financial Officer2026-05-21A5,000——CommonForm 4 ↗
Christopher YeaChief Development Officer2026-05-21D3,75000Derivative, Class A CommonForm 4 ↗
Brian PiekosChief Financial Officer2026-05-22D1,4892739,882CommonForm 4 ↗
Nicole SweenyChief Commercial Officer2026-05-22D1,8612749,846CommonForm 4 ↗
Paul AudhyaChief Medical Officer2026-05-22D5,00000Derivative, Class A CommonForm 4 ↗
Nicole SweenyChief Commercial Officer2026-05-22D5,00000Derivative, Class A CommonForm 4 ↗
Nicole SweenyChief Commercial Officer2026-05-22A5,000——CommonForm 4 ↗
Christopher YeaChief Development Officer2026-05-22D3,12500Derivative, Class A CommonForm 4 ↗
Christopher YeaChief Development Officer2026-05-22D2,3582763,158CommonForm 4 ↗
Benjamin PalleikoDirector2026-05-22D10,92627292,646CommonForm 4 ↗
Christopher YeaChief Development Officer2026-05-22A3,125——CommonForm 4 ↗
Paul AudhyaChief Medical Officer2026-05-22D2,6852771,916CommonForm 4 ↗
Paul AudhyaChief Medical Officer2026-05-22A5,000——CommonForm 4 ↗
Paul AudhyaChief Medical Officer2026-05-26D2,2392759,955CommonForm 4 ↗
Christopher YeaChief Development Officer2026-05-26D1,9662752,645CommonForm 4 ↗
Nicole SweenyChief Commercial Officer2026-05-26D1,4892739,872CommonForm 4 ↗
Christopher YeaChief Development Officer2026-05-27D33,80000Derivative, Class A CommonForm 4 ↗
Christopher YeaChief Development Officer2026-05-27D33,80027905,225CommonForm 4 ↗
Christopher YeaChief Development Officer2026-05-27A33,8007238,966CommonForm 4 ↗
Edward W. UnkartDirector2026-06-11D30,000——Derivative, Class A CommonForm 4 ↗
Edward W. UnkartDirector2026-06-11D7,000——Derivative, Class A CommonForm 4 ↗
Bilal ArifChief Operations Officer2026-06-11D100,000——Derivative, Class A CommonForm 4 ↗
Nicole SweenyChief Commercial Officer2026-06-11D93,750——Derivative, Class A CommonForm 4 ↗
Patrick TreanorDirector2026-06-11D17,000——Derivative, Class A CommonForm 4 ↗
Bethany SensenigDirector2026-06-11D45,000——Derivative, Class A CommonForm 4 ↗
Paul AudhyaChief Medical Officer2026-06-11D68,750——Derivative, Class A CommonForm 4 ↗
Paul AudhyaChief Medical Officer2026-06-11D40,000——Derivative, Class A CommonForm 4 ↗
Paul AudhyaChief Medical Officer2026-06-11D150,26000CommonForm 4 ↗
Brian JG PereiraDirector2026-06-11D30,000——Derivative, Class A CommonForm 4 ↗
Brian JG PereiraDirector2026-06-11D10,000——Derivative, Class A CommonForm 4 ↗
Brian JG PereiraDirector2026-06-11D10,000——Derivative, Class A CommonForm 4 ↗
Nancy StuartDirector2026-06-11D10,000——Derivative, Class A CommonForm 4 ↗
Nancy StuartDirector2026-06-11D10,000——Derivative, Class A CommonForm 4 ↗
Edward W. UnkartDirector2026-06-11D10,000——Derivative, Class A CommonForm 4 ↗
Brian PiekosChief Financial Officer2026-06-11D93,750——Derivative, Class A CommonForm 4 ↗
Brian PiekosChief Financial Officer2026-06-11D55,000——Derivative, Class A CommonForm 4 ↗
Christopher YeaChief Development Officer2026-06-11D41,250——Derivative, Class A CommonForm 4 ↗
Christopher YeaChief Development Officer2026-06-11D18,920——Derivative, Class A CommonForm 4 ↗
Christopher YeaChief Development Officer2026-06-11D20,000——Derivative, Class A CommonForm 4 ↗
Christopher YeaChief Development Officer2026-06-11D27,900——Derivative, Class A CommonForm 4 ↗
Christopher YeaChief Development Officer2026-06-11D52,600——Derivative, Class A CommonForm 4 ↗
Christopher YeaChief Development Officer2026-06-11D229,91800CommonForm 4 ↗
Benjamin PalleikoDirector2026-06-11D304,688——Derivative, Class A CommonForm 4 ↗
Benjamin PalleikoDirector2026-06-11D92,560——Derivative, Class A CommonForm 4 ↗
Benjamin PalleikoDirector2026-06-11D125,001——Derivative, Class A CommonForm 4 ↗
Benjamin PalleikoDirector2026-06-11D113,920——Derivative, Class A CommonForm 4 ↗
Benjamin PalleikoDirector2026-06-11D40,000——Derivative, Class A CommonForm 4 ↗
Benjamin PalleikoDirector2026-06-11D25,800——Derivative, Class A CommonForm 4 ↗
Benjamin PalleikoDirector2026-06-11D37,500——Derivative, Class A CommonForm 4 ↗
Benjamin PalleikoDirector2026-06-11D85,000——Derivative, Class A CommonForm 4 ↗
Benjamin PalleikoDirector2026-06-11D75,000——Derivative, Class A CommonForm 4 ↗
Benjamin PalleikoDirector2026-06-11D33,750——Derivative, Class A CommonForm 4 ↗
Benjamin PalleikoDirector2026-06-11D71,700——Derivative, Class A CommonForm 4 ↗
Benjamin PalleikoDirector2026-06-11D33,800——Derivative, Class A CommonForm 4 ↗
Benjamin PalleikoDirector2026-06-11D47,354——Derivative, Class A CommonForm 4 ↗
Brian PiekosChief Financial Officer2026-06-11D100,000——Derivative, Class A CommonForm 4 ↗
Christopher YeaChief Development Officer2026-06-11D80,000——Derivative, Class A CommonForm 4 ↗
Christopher YeaChief Development Officer2026-06-11D31,000——Derivative, Class A CommonForm 4 ↗
Benjamin PalleikoDirector2026-06-11D479,98900CommonForm 4 ↗
Edward W. UnkartDirector2026-06-11D10,000——Derivative, Class A CommonForm 4 ↗
Nicole SweenyChief Commercial Officer2026-06-11D59,29100CommonForm 4 ↗
Paul AudhyaChief Medical Officer2026-06-11D25,800——Derivative, Class A CommonForm 4 ↗
Brian JG PereiraDirector2026-06-11D10,000——Derivative, Class A CommonForm 4 ↗
Brian JG PereiraDirector2026-06-11D7,000——Derivative, Class A CommonForm 4 ↗
Patrick TreanorDirector2026-06-11D30,000——Derivative, Class A CommonForm 4 ↗
Patrick TreanorDirector2026-06-11D10,000——Derivative, Class A CommonForm 4 ↗
Brian PiekosChief Financial Officer2026-06-11D21,66100CommonForm 4 ↗
Christopher YeaChief Development Officer2026-06-11D25,000——Derivative, Class A CommonForm 4 ↗
Benjamin PalleikoDirector2026-06-11D20,000——Derivative, Class A CommonForm 4 ↗
Christopher YeaChief Development Officer2026-06-11D60,000——Derivative, Class A CommonForm 4 ↗
Christopher YeaChief Development Officer2026-06-11D53,500——Derivative, Class A CommonForm 4 ↗
Paul AudhyaChief Medical Officer2026-06-11D93,750——Derivative, Class A CommonForm 4 ↗
Paul AudhyaChief Medical Officer2026-06-11D100,000——Derivative, Class A CommonForm 4 ↗
Benjamin PalleikoDirector2026-06-11D255,750——Derivative, Class A CommonForm 4 ↗
Benjamin PalleikoDirector2026-06-11D29,611——Derivative, Class A CommonForm 4 ↗
Nancy StuartDirector2026-06-11D14,000——Derivative, Class A CommonForm 4 ↗
Benjamin PalleikoDirector2026-06-11D52,600——Derivative, Class A CommonForm 4 ↗
Edward W. UnkartDirector2026-06-11D10,000——Derivative, Class A CommonForm 4 ↗
Edward W. UnkartDirector2026-06-11D7,000——Derivative, Class A CommonForm 4 ↗
Edward W. UnkartDirector2026-06-11D7,000——Derivative, Class A CommonForm 4 ↗
Edward W. UnkartDirector2026-06-11D10,000——Derivative, Class A CommonForm 4 ↗
Edward W. UnkartDirector2026-06-11D6,000——Derivative, Class A CommonForm 4 ↗
Edward W. UnkartDirector2026-06-11D12,000——Derivative, Class A CommonForm 4 ↗
Laurence ReidDirector2026-06-11D17,000——Derivative, Class A CommonForm 4 ↗
Bilal ArifChief Operations Officer2026-06-11D49,000——Derivative, Class A CommonForm 4 ↗
Nicole SweenyChief Commercial Officer2026-06-11D68,750——Derivative, Class A CommonForm 4 ↗
Nicole SweenyChief Commercial Officer2026-06-11D40,000——Derivative, Class A CommonForm 4 ↗
Nicole SweenyChief Commercial Officer2026-06-11D100,000——Derivative, Class A CommonForm 4 ↗
Patrick TreanorDirector2026-06-11D10,000——Derivative, Class A CommonForm 4 ↗
William FaireyDirector2026-06-11D30,000——Derivative, Class A CommonForm 4 ↗
William FaireyDirector2026-06-11D10,000——Derivative, Class A CommonForm 4 ↗
William FaireyDirector2026-06-11D17,000——Derivative, Class A CommonForm 4 ↗
Brian JG PereiraDirector2026-06-11D10,000——Derivative, Class A CommonForm 4 ↗
Brian JG PereiraDirector2026-06-11D14,000——Derivative, Class A CommonForm 4 ↗
Nancy StuartDirector2026-06-11D30,000——Derivative, Class A CommonForm 4 ↗
Nancy StuartDirector2026-06-11D10,000——Derivative, Class A CommonForm 4 ↗
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20252025-10-0133,600,8083,985,8605,11289.4%Passed
20242024-10-0326,578,8054,459,36336,75085.63%Passed
20242024-10-0326,578,8054,459,36336,75085.63%Passed
20232023-09-2620,001,3482,652,1341,81088.29%Passed
20222022-10-1317,693,8661,588,8841,66391.76%Passed
20212021-09-3019,696,0802,450,45052688.94%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20252025-10-0189.4%a
20242024-10-0385.63%b
20242024-10-0385.63%c

a. Voting standard not stated in the filing.

b. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not be counted to determine whether a nominee receives a majority of votes cast.”.

c. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not be counted to determine whether a nominee receives a majority of votes cast.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

09

Board fee structure and ownership guideline

Annual cash retainer$42,500
Annual equity retainer—
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)20,000 / 15,000 / 10,000
Stock ownership guideline—
10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1KalVista Pharmaceuticals, Inc.2025Benjamin Palleiko$688,272$3,731,160$0$0$5,094,999

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10d

Frequently asked questions

Who was the highest-paid executive at KalVista Pharmaceuticals, Inc. in fiscal 2025?
As disclosed, Benjamin Palleiko (Chief Executive Officer) was the highest-paid executive at KalVista Pharmaceuticals, Inc. in fiscal 2025, with total compensation of $5,094,999.
How did shareholders vote on KalVista Pharmaceuticals, Inc.'s executive compensation?
As disclosed, 89.4% of shareholders supported KalVista Pharmaceuticals, Inc.'s executive compensation in the latest say-on-pay vote.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Benjamin Palleiko10-K/A2026-04-300001193125-26-197556Section “Summary Compensation Table”. As printed: 5,094,999. Filing ↗
2Section 01, Paul Audhya10-K/A2026-04-300001193125-26-197556Section “Summary Compensation Table”. As printed: 2,789,094. Filing ↗
3Section 01, Brian PiekosDEF 14A2025-08-210001193125-25-185353Section “Summary Compensation Table”. As printed: 2,144,133. Filing ↗machine: t76 · r5 · c25 · span 296302–296311
4Section 01, Bilal Arif10-K/A2026-04-300001193125-26-197556Section “Summary Compensation Table”. As printed: 954,783. Filing ↗
5Section 02, Benjamin Palleiko 2026-05-11Form 42026-05-130001366244-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
6Section 02, Benjamin Palleiko 2026-05-11Form 42026-05-130001366244-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
7Section 02, Benjamin Palleiko 2026-05-12Form 42026-05-130001366244-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
8Section 02, Benjamin Palleiko 2026-05-17Form 42026-05-190001366244-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
9Section 02, Benjamin Palleiko 2026-05-17Form 42026-05-190001366244-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
10Section 02, Paul Audhya 2026-05-17Form 42026-05-190001860131-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
11Section 02, Christopher Yea 2026-05-17Form 42026-05-190001691102-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
12Section 02, Christopher Yea 2026-05-17Form 42026-05-190001691102-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
13Section 02, Paul Audhya 2026-05-17Form 42026-05-190001860131-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
14Section 02, Christopher Yea 2026-05-18Form 42026-05-190001691102-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
15Section 02, Benjamin Palleiko 2026-05-18Form 42026-05-190001366244-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
16Section 02, Paul Audhya 2026-05-18Form 42026-05-190001860131-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
17Section 02, Brian Piekos 2026-05-21Form 42026-05-260001815308-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
18Section 02, Paul Audhya 2026-05-21Form 42026-05-260001860131-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
19Section 02, Christopher Yea 2026-05-21Form 42026-05-260001691102-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
20Section 02, Nicole Sweeny 2026-05-21Form 42026-05-260001827505-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
21Section 02, Nicole Sweeny 2026-05-21Form 42026-05-260001827505-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
22Section 02, Paul Audhya 2026-05-21Form 42026-05-260001860131-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
23Section 02, Benjamin Palleiko 2026-05-21Form 42026-05-260001366244-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
24Section 02, Benjamin Palleiko 2026-05-21Form 42026-05-260001366244-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
25Section 02, Brian Piekos 2026-05-21Form 42026-05-260001815308-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
26Section 02, Christopher Yea 2026-05-21Form 42026-05-260001691102-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
27Section 02, Brian Piekos 2026-05-22Form 42026-05-260001815308-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
28Section 02, Nicole Sweeny 2026-05-22Form 42026-05-260001827505-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
29Section 02, Paul Audhya 2026-05-22Form 42026-05-270001860131-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
30Section 02, Nicole Sweeny 2026-05-22Form 42026-05-270001827505-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, Nicole Sweeny 2026-05-22Form 42026-05-270001827505-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, Christopher Yea 2026-05-22Form 42026-05-270001691102-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, Christopher Yea 2026-05-22Form 42026-05-260001691102-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, Benjamin Palleiko 2026-05-22Form 42026-05-260001366244-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, Christopher Yea 2026-05-22Form 42026-05-270001691102-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, Paul Audhya 2026-05-22Form 42026-05-260001860131-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, Paul Audhya 2026-05-22Form 42026-05-270001860131-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, Paul Audhya 2026-05-26Form 42026-05-270001860131-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, Christopher Yea 2026-05-26Form 42026-05-270001691102-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Nicole Sweeny 2026-05-26Form 42026-05-270001827505-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Christopher Yea 2026-05-27Form 42026-05-290001691102-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, Christopher Yea 2026-05-27Form 42026-05-290001691102-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Christopher Yea 2026-05-27Form 42026-05-290001691102-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Edward W. Unkart 2026-06-11Form 42026-06-110001306267-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, Edward W. Unkart 2026-06-11Form 42026-06-110001306267-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, Bilal Arif 2026-06-11Form 42026-06-110001959750-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, Nicole Sweeny 2026-06-11Form 42026-06-110001827505-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, Patrick Treanor 2026-06-11Form 42026-06-110001929863-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, Bethany Sensenig 2026-06-11Form 42026-06-110001899935-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Paul Audhya 2026-06-11Form 42026-06-110001860131-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Paul Audhya 2026-06-11Form 42026-06-110001860131-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Paul Audhya 2026-06-11Form 42026-06-110001860131-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, Brian JG Pereira 2026-06-11Form 42026-06-110001298146-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, Brian JG Pereira 2026-06-11Form 42026-06-110001298146-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
55Section 02, Brian JG Pereira 2026-06-11Form 42026-06-110001298146-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
56Section 02, Nancy Stuart 2026-06-11Form 42026-06-110001594774-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
57Section 02, Nancy Stuart 2026-06-11Form 42026-06-110001594774-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
58Section 02, Edward W. Unkart 2026-06-11Form 42026-06-110001306267-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
59Section 02, Brian Piekos 2026-06-11Form 42026-06-110001815308-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
60Section 02, Brian Piekos 2026-06-11Form 42026-06-110001815308-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
61Section 02, Christopher Yea 2026-06-11Form 42026-06-110001691102-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
62Section 02, Christopher Yea 2026-06-11Form 42026-06-110001691102-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
63Section 02, Christopher Yea 2026-06-11Form 42026-06-110001691102-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
64Section 02, Christopher Yea 2026-06-11Form 42026-06-110001691102-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
65Section 02, Christopher Yea 2026-06-11Form 42026-06-110001691102-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
66Section 02, Christopher Yea 2026-06-11Form 42026-06-110001691102-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
67Section 02, Benjamin Palleiko 2026-06-11Form 42026-06-110001366244-26-000012Insider equity transaction reported since the proxy statement. Filing ↗
68Section 02, Benjamin Palleiko 2026-06-11Form 42026-06-110001366244-26-000012Insider equity transaction reported since the proxy statement. Filing ↗
69Section 02, Benjamin Palleiko 2026-06-11Form 42026-06-110001366244-26-000012Insider equity transaction reported since the proxy statement. Filing ↗
70Section 02, Benjamin Palleiko 2026-06-11Form 42026-06-110001366244-26-000012Insider equity transaction reported since the proxy statement. Filing ↗
71Section 02, Benjamin Palleiko 2026-06-11Form 42026-06-110001366244-26-000012Insider equity transaction reported since the proxy statement. Filing ↗
72Section 02, Benjamin Palleiko 2026-06-11Form 42026-06-110001366244-26-000012Insider equity transaction reported since the proxy statement. Filing ↗
73Section 02, Benjamin Palleiko 2026-06-11Form 42026-06-110001366244-26-000012Insider equity transaction reported since the proxy statement. Filing ↗
74Section 02, Benjamin Palleiko 2026-06-11Form 42026-06-110001366244-26-000012Insider equity transaction reported since the proxy statement. Filing ↗
75Section 02, Benjamin Palleiko 2026-06-11Form 42026-06-110001366244-26-000012Insider equity transaction reported since the proxy statement. Filing ↗
76Section 02, Benjamin Palleiko 2026-06-11Form 42026-06-110001366244-26-000012Insider equity transaction reported since the proxy statement. Filing ↗
77Section 02, Benjamin Palleiko 2026-06-11Form 42026-06-110001366244-26-000012Insider equity transaction reported since the proxy statement. Filing ↗
78Section 02, Benjamin Palleiko 2026-06-11Form 42026-06-110001366244-26-000012Insider equity transaction reported since the proxy statement. Filing ↗
79Section 02, Benjamin Palleiko 2026-06-11Form 42026-06-110001366244-26-000012Insider equity transaction reported since the proxy statement. Filing ↗
80Section 02, Brian Piekos 2026-06-11Form 42026-06-110001815308-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
81Section 02, Christopher Yea 2026-06-11Form 42026-06-110001691102-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
82Section 02, Christopher Yea 2026-06-11Form 42026-06-110001691102-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
83Section 02, Benjamin Palleiko 2026-06-11Form 42026-06-110001366244-26-000012Insider equity transaction reported since the proxy statement. Filing ↗
84Section 02, Edward W. Unkart 2026-06-11Form 42026-06-110001306267-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
85Section 02, Nicole Sweeny 2026-06-11Form 42026-06-110001827505-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
86Section 02, Paul Audhya 2026-06-11Form 42026-06-110001860131-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
87Section 02, Brian JG Pereira 2026-06-11Form 42026-06-110001298146-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
88Section 02, Brian JG Pereira 2026-06-11Form 42026-06-110001298146-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
89Section 02, Patrick Treanor 2026-06-11Form 42026-06-110001929863-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
90Section 02, Patrick Treanor 2026-06-11Form 42026-06-110001929863-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
91Section 02, Brian Piekos 2026-06-11Form 42026-06-110001815308-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
92Section 02, Christopher Yea 2026-06-11Form 42026-06-110001691102-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
93Section 02, Benjamin Palleiko 2026-06-11Form 42026-06-110001366244-26-000012Insider equity transaction reported since the proxy statement. Filing ↗
94Section 02, Christopher Yea 2026-06-11Form 42026-06-110001691102-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
95Section 02, Christopher Yea 2026-06-11Form 42026-06-110001691102-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
96Section 02, Paul Audhya 2026-06-11Form 42026-06-110001860131-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
97Section 02, Paul Audhya 2026-06-11Form 42026-06-110001860131-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
98Section 02, Benjamin Palleiko 2026-06-11Form 42026-06-110001366244-26-000012Insider equity transaction reported since the proxy statement. Filing ↗
99Section 02, Benjamin Palleiko 2026-06-11Form 42026-06-110001366244-26-000012Insider equity transaction reported since the proxy statement. Filing ↗
100Section 02, Nancy Stuart 2026-06-11Form 42026-06-110001594774-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
101Section 02, Benjamin Palleiko 2026-06-11Form 42026-06-110001366244-26-000012Insider equity transaction reported since the proxy statement. Filing ↗
102Section 02, Edward W. Unkart 2026-06-11Form 42026-06-110001306267-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
103Section 02, Edward W. Unkart 2026-06-11Form 42026-06-110001306267-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
104Section 02, Edward W. Unkart 2026-06-11Form 42026-06-110001306267-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
105Section 02, Edward W. Unkart 2026-06-11Form 42026-06-110001306267-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
106Section 02, Edward W. Unkart 2026-06-11Form 42026-06-110001306267-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
107Section 02, Edward W. Unkart 2026-06-11Form 42026-06-110001306267-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
108Section 02, Laurence Reid 2026-06-11Form 42026-06-110001492749-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
109Section 02, Bilal Arif 2026-06-11Form 42026-06-110001959750-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
110Section 02, Nicole Sweeny 2026-06-11Form 42026-06-110001827505-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
111Section 02, Nicole Sweeny 2026-06-11Form 42026-06-110001827505-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
112Section 02, Nicole Sweeny 2026-06-11Form 42026-06-110001827505-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
113Section 02, Patrick Treanor 2026-06-11Form 42026-06-110001929863-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
114Section 02, William Fairey 2026-06-11Form 42026-06-110001727275-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
115Section 02, William Fairey 2026-06-11Form 42026-06-110001727275-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
116Section 02, William Fairey 2026-06-11Form 42026-06-110001727275-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
117Section 02, Brian JG Pereira 2026-06-11Form 42026-06-110001298146-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
118Section 02, Brian JG Pereira 2026-06-11Form 42026-06-110001298146-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
119Section 02, Nancy Stuart 2026-06-11Form 42026-06-110001594774-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
120Section 02, Nancy Stuart 2026-06-11Form 42026-06-110001594774-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
121Section 06, 2025 voteForm 8-K2025-10-020001193125-25-227478Item 5.07 · say-on-pay result. As reported: 89.4% (votes for as printed: 33,600,808). Filing ↗
122Section 06, 2024 voteForm 8-K2024-10-040000950170-24-112904Item 5.07 · say-on-pay result. As reported: 85.63% (votes for as printed: 26,578,805). Filing ↗
123Section 06, 2024 voteForm 8-K2024-10-040000950170-24-112904Item 5.07 · say-on-pay result. As reported: 85.63% (votes for as printed: 26,578,805). Filing ↗
124Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
125KalVista Pharmaceuticals, Inc. (subject), Section 10b CEO total10-K/A2026-04-300001193125-26-197556CEO total compensation as printed in KalVista Pharmaceuticals, Inc.'s own proxy. As printed: 5,094,999. Filing ↗

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.

Get the KalVista Pharmaceuticals, Inc. Executive Compensation Report

$1,500

Buy the report - $1,500Both reports - $2,400
KALV Peer Teardown Report